Insider buying last 90 days
No open-market insider purchases were filed for GLUE in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every GLUE insider filing, plotted on the chart in Gekko.Open GLUE in Gekko
NASDAQ: GLUE
Monte Rosa Therapeutics (GLUE) Stock Analysis & Forecast
Oct 12 close
$10.52+0.22 (+2.1%)
Gekko Brief
AI summaryOct 12 closeMonte Rosa Therapeutics released positive Phase 1 data from its GFORCE-1 study of MRT-8102, a NEK7-directed molecular glue degrader, showing biomarker reductions in subjects with elevated cardiovascular disease risk and a safety profile comparable to placebo. HC Wainwright & Co. reiterated a Buy rating with a $25.00 price target following the readout, and brokers have set expectations for a Q3 2026 loss of $0.45 per share ahead of the company's next report.
Shares closed at $10.52, up 2.1% on the day, but remain below both the 50-day average of $13.48 and the 200-day average of $18.00, with the 50-day below the 200-day. Over the past month the stock is down 25.2%, and over three months down 55.2%. The GekkoIndex reads 70.4, placing GLUE in the Buying zone, and the current price sits 55.8% below the Gekko Fair Value of $23.78.
GLUE's next earnings report is set for 5 November 2026, before the open, 24 days away and inside a typical 20-trading-day holding window; the prior quarter missed estimates with an actual loss of $0.43 per share against a $0.38 estimate, producing a 1.7% reaction. No insider, Congress or unusual options activity appears in the current windows. Seasonality from this point in the calendar has averaged a 27.6% move over the next 20 trading days across 5 years, rising in 4 of them. Analyst coverage from 8 firms carries a consensus target of $28.00.
Written by AI from the Oct 12, 2026 close and checked automatically against the figures on this page.
Monte Rosa Therapeutics price vs fair value
Close $10.52200-day averageGekko Fair Value $23.78
Monte Rosa Therapeutics quick facts
- Market cap
- $888.7M
- P/E ratio
- —
- Forward P/E
- 10
- EPS, TTM
- −$1.75
- Revenue, TTM
- $28.73M
- Profit margin
- 0%
- Dividend yield
- —
- Beta
- 1.37
- Volume
- 1.83M avg 1.40M
- 1-year return
- +24.3%
- Typical daily move
- ±6.2%
- Typical 20-day move
- ±16.3%
- 50-day average
- $13.48
- 200-day average
- $18.00
- Next earnings
- Nov 5 before open
- Shares outstanding
- 85.31M
Monte Rosa Therapeutics swing-trade checklist
Monte Rosa Therapeutics scores 3 supportive, 0 mixed and 2 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive0 mixed2 headwinds
- Trendheadwind
Below 50 and 200-day
Close $10.52 is below the 50-day ($13.48) and 200-day ($18.00) averages, and the 50-day is below the 200-day.
See the chart - GekkoIndexsupportive
70.4, Buying
Reading 70.4 is in the Buying zone.
See the GekkoIndex - Fair valuesupportive
55.8% below
Price is 55.8% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings riskheadwind
Reports in 24 days
Reports on Nov 5, 2026, 24 days away — inside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+27.6% on average
From this point in the calendar, the next 20 trading days averaged +27.6% over 5 years, rising in 4 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Monte Rosa Therapeutics stock chart and price history
Monte Rosa Therapeutics closed at $10.52 on Oct 12, 2026, +24.3% over the past year, inside a 52-week range of $8.53 to $25.77.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −25.2%
- 3 months
- −55.2%
- 6 months
- −40.1%
- 1 year
- +24.3%
The full GLUE chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open GLUE in Gekko
Follow Monte Rosa Therapeutics through every session
Put GLUE on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track GLUE in GekkoFree for 7 days. No credit card required.
About Monte Rosa Therapeutics
Monte Rosa Therapeutics works on small-molecule medicines designed around the idea of breaking down specific proteins using the body's own disposal systems. Its best-known program is an oral compound aimed at GSPT1, a protein tied to translation termination, with the goal of treating cancers driven by Myc. The company is working toward precision treatments rather than broader therapies, targeting disease at the level of individual proteins.
Beyond its lead program, Monte Rosa has several other research efforts underway. These include work on CDK2 for cancers of the ovaries, uterus, and breast, and on NEK7 for inflammatory conditions such as Crohn's disease, neurodegenerative disorders, diabetes, and liver disease. It is also studying VAV1 in connection with autoimmune disorders and BCL11A for hemoglobinopathies, reflecting a pipeline spread across oncology, inflammation, and blood-related disease.
Monte Rosa Therapeutics was established in 2019 and is headquartered in Boston, Massachusetts. Its shares are listed on the NASDAQ under the ticker GLUE.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Biotechnology
- Website
- monterosatx.com
Monte Rosa Therapeutics GekkoIndex: the smart money zone
Monte Rosa Therapeutics’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 70.4, in the Buying zone, down 6 points over five sessions.
70.4Buying
Down 6 points over five sessions.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying (current zone) | 46 | +1.0% | +7.6% | ||
| Accumulation | 246 | +1.1% | +5.7% | ||
| Neutral | 352 | +2.0% | +6.4% | ||
| Distribution | 35 | −2.1% | +0.8% | ||
| Selling | 3 | Too few readings yet | |||
Average GLUE share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Buying readings averaged +3.1% over 20 days. Past behaviour doesn’t guarantee future results.
Buying zone: Smart money likely accumulating heavily. About the five zones →
See every daily GekkoIndex reading plotted over the GLUE price, zone by zone.Track GLUE in Gekko
Is Monte Rosa Therapeutics stock overvalued? Gekko Fair Value
Monte Rosa Therapeutics trades 55.8% below Gekko Fair Value of $23.78, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Monte Rosa Therapeutics shares are worth, recalculated every trading day.
$23.78
Gekko Fair Value, Oct 10, 2026
55.8% Undervalued
Gekko Fair Value on every chart, with the gap to price updating daily.Open GLUE in Gekko
Monte Rosa Therapeutics insider and Congress trading
No open-market insider purchases were filed for Monte Rosa Therapeutics, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in GLUE were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for GLUE, plotted on the chart in Gekko.Open GLUE in Gekko
Buybacks
Monte Rosa Therapeutics has been buying back its own shares.
- Bought back, year ended Dec 31, 2024
- $641K
- As a share of market cap
- 0.07%
From company filings.
Hedge funds and billionaires quarter ended Jun 30
1of the funds Gekko tracks holds GLUE.
0added1opened0trimmed1sold out
Which funds are on each side, name by name.Unlock in Gekko
Monte Rosa Therapeutics earnings: next date and track record
Monte Rosa Therapeutics reports on Nov 5, 2026, before the open (24 days away), and beat the EPS estimate in 6 of its last 8 reports.
Next earnings report
Nov 5, 2026
Expected before the open, 24 days away
- EPS estimate
- −$0.24
- Revenue estimate
- $31.47M
6 of 8reports beat the EPS estimate
±4%average move across the report
3 of 8reports followed by a gain
Share-price move across each report
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 6, 2026 | −$0.43 est −$0.38 | $9.00M est $12.91M | +1.7% |
| May 7, 2026 | −$0.45 est −$0.48 | $4.20M est $10.95M | −4.9% |
| Mar 17, 2026 | −$0.55 est −$0.33 | $2.80M est $15.55M | −3.6% |
| Nov 6, 2025 | −$0.33 est −$0.37 | $12.77M est $15.51M | 0.0% |
| Aug 7, 2025 | −$0.15 est −$0.38 | $23.19M est $7.77M | +0.5% |
| May 8, 2025 | $0.57 est $0.00 | $84.93M est $13.57M | +6.2% |
| Mar 20, 2025 | $0.23 est $0.02 | $60.65M est $46.67M | −13.4% |
| Nov 7, 2024 | −$0.29 est −$0.49 | $9.22M est $2.64M | −2.0% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Monte Rosa Therapeutics stock forecast and analyst price targets
Analysts’ average 12-month price target for Monte Rosa Therapeutics is $28.00, +166.2% from the last close, from 8 firms rating the stock in the last 90 days.
$28.00consensus 12-month target, +166.2% from the last close
Now $10.52Avg $28.00
Low $19High $37
Each firm’s latest rating in the last 90 days: 8 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Oct 11 | UBS | $19 | +80.6% |
| Oct 5 | H.C. Wainwright | $25 | +137.6% |
| Oct 2 | Wedbush | $27 | +156.7% |
| Oct 2 | Wedbush | $27 | +156.7% |
| Oct 2 | Piper Sandler | $37 | +251.7% |
+7.6%average 20-day move after past Buying readings
+27.6%average move over the next 20 trading days in the last 5 years
±6.2%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Monte Rosa Therapeutics seasonality: the next 20 trading days
Over the next 20 trading days from Oct 10, Monte Rosa Therapeutics averaged +27.6% across the last 5 years, rising in 4 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +5.7% | 4 of 5 |
| Next 10 trading days | 0.0% | 4 of 5 |
| Next 15 trading days | +29.6% | 4 of 5 |
| Next 20 trading days | +27.6% | 4 of 5 |
| Next 30 trading days | +19.5% | 4 of 5 |
For scale, GLUE’s typical 20-trading-day move in either direction is about 16.3%.
Monte Rosa Therapeutics market cap and key statistics
Monte Rosa Therapeutics’s market cap is $888.7M and revenue of $28.73M over the last twelve months.
Valuation
- Market cap
- $888.7M
- Forward P/E
- 10
- EPS, TTM
- −$1.75
- Gekko Fair Value
- $23.78
Trading
- Volume
- 1.83M
- Avg volume, 20 days
- 1.40M
- 52-week high
- $25.77
- 52-week low
- $8.53
- Shares outstanding
- 85.31M
Financials
- Revenue, TTM
- $28.73M
- Profit margin
- 0%
- Return on equity
- -42.7%
- Quarterly earnings growth, YoY
- 0.0%
Risk and income
- Beta
- 1.37
- Typical daily move
- ±6.2%
- Typical 20-day move
- ±16.3%
Monte Rosa Therapeutics stock news this week
Coverage of Monte Rosa Therapeutics this week reads positive: 4 positive, 2 neutral and 0 negative headlines.
- ImmunityBio (NASDAQ:IBRX) vs. Monte Rosa Therapeutics (NASDAQ:GLUE) Financial SurveyDefense World, Oct 11
- Monte Rosa Therapeutics Inc (GLUE-Q) Stock Price and NewsThe Globe and Mail, Oct 7
- Monte Rosa's MRT-8102 Shows Biomarker Gains in GFORCE-1 StudyYahoo Finance, Oct 6
- Monte Rosa Therapeutics to Present Results of MRT-8102 GFORCE-1 Phase 1 Study in Subjects with Elevated Cardiovascular Disease RiskYahoo Finance Singapore, Oct 5
- Monte Rosa Therapeutics (GLUE) Following Phase 1 Data Faces A Big Fair Value QuestionSimply Wall Street, Oct 5
- HC Wainwright & Co. reiterates Buy rating on Monte Rosa Therapeutics, $25 price targetTradingView, Oct 5
Monte Rosa Therapeutics peers
Monte Rosa Therapeutics’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| AMGNAmgen | Neutral | 25.5% below |
| GILDGilead Sciences | Neutral | 4.2% above |
| MRNAModerna | Neutral | 62.7% above |
| NTRANatera | Neutral | 10.3% above |
| IQVIQVIA | Neutral | 8.4% above |
| UTHRUnited Therapeutics | Neutral | 14.4% below |
A peer links to its own page where one exists.
Monte Rosa Therapeutics stock FAQ
What is Monte Rosa Therapeutics’s market cap?
Monte Rosa Therapeutics’s market cap is $888.7M at the Oct 12, 2026 close of $10.52, with 85.31M shares outstanding.
What is the Monte Rosa Therapeutics stock forecast?
The consensus analyst 12-month price target for Monte Rosa Therapeutics is $28.00, +166.2% from the last close. Of the 8 firms that rated the stock in the last 90 days, 8 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Monte Rosa Therapeutics stock overvalued or undervalued?
On Gekko’s estimate Monte Rosa Therapeutics is undervalued: the Oct 12, 2026 close of $10.52 is 55.8% below Gekko Fair Value of $23.78. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Monte Rosa Therapeutics report earnings next?
Monte Rosa Therapeutics is expected to report on Nov 5, 2026, before the market opens (24 days away). Analysts expect earnings of −$0.24 per share on revenue of $31.47M. Monte Rosa Therapeutics beat the earnings estimate in 6 of its last 8 reports, moving 4% on average across the report.
What is Monte Rosa Therapeutics’s 52-week high and low?
Monte Rosa Therapeutics’s 52-week high is $25.77 and its 52-week low is $8.53; it closed at $10.52 on Oct 12, 2026, +24.3% over the past year. Over the last five years the shares peaked at $27.57 on Oct 29, 2021.
Is Monte Rosa Therapeutics stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (gekkoindex, fair value and seasonality) and 2 as headwinds (trend and earnings risk). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Monte Rosa Therapeutics the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.